Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma
Phase of Trial: Phase 0
Latest Information Update: 11 Sep 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.
- 01 May 2018 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.
- 01 May 2018 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.